Thenappan Research Published in JACC

Exciting news for the pulmonary hypertension (PAH) community! Our new publication, "Microbiota Transplant Therapy Is Safe and Feasible in Pulmonary Arterial Hypertension," is now live in JACC: Basic to Translational Science. This marks a significant step forward as it's the first human pilot trial to study microbiota transplant therapy (MTT) in PAH patients.

The study enrolled 11 patients and found that MTT is safe and feasible, with no serious or severe adverse events related to the treatment. We observed that the therapy was associated with a transient reduction in circulating proinflammatory cytokines and a modest level of donor bacterial engraftment. While the study did not show statistically significant changes, we did observe positive trends, including an increase in the six-minute walk distance and an improvement in quality of life scores.

These findings suggest that modulating the gut microbiome may be a promising new therapeutic strategy for PAH. We are hopeful that this research will pave the way for further investigation into new treatment options for patients.